Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZD0530 + carboplatin + paclitaxel
- Development stage
- Phase 2
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of AZD0530 (saracatinib), carboplatin, and paclitaxel. **AZD0530 (saracatinib)** is an orally available dual kinase inhibitor that selectively inhibits Src family kinases and Bcr-Abl tyrosine kinase. It is being developed primarily by AstraZeneca. *Carboplatin* is a platinum-based chemotherapeutic agent that forms DNA crosslinks, interfering with DNA repair and replication. *Paclitaxel* is a microtubule-stabilizing agent that inhibits cell division. The combination is being explored for the treatment of advanced ovarian cancer, aiming to enhance standard chemotherapy efficacy by targeting complementary oncogenic pathways: Src family kinases (cell survival, migration), DNA structure (crosslinking), and microtubule dynamics (mitosis inhibition)[3][4][6][7][8].
- Other names
- saracatinib + carboplatin + paclitaxel
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)SFK (SRC family kinases)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on AZD0530 + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZD0530 + carboplatin + paclitaxel.